Aimmune Therapeutics (AIMT) Receiving Favorable Press Coverage, AlphaOne Reports
Headlines about Aimmune Therapeutics (NASDAQ:AIMT) have been trending positive on Saturday, Alpha One reports. The research group, a service of Accern, identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a daily sentiment score of 0.26 on Alpha One’s scale. Alpha One also assigned press coverage about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Alpha One Sentiment’s rankings:
- Aimmune Therapeutics (AIMT) to Present Data on Peanut Allergy in Europe at EAACI (streetinsider.com)
- Aimmune Therapeutics : to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th (4-traders.com)
- Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 (finance.yahoo.com)
- Aimmune Therapeutics, Inc. (AIMT) Lifted to “Hold” at ValuEngine (americanbankingnews.com)
- Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy (finance.yahoo.com)
Aimmune Therapeutics (NASDAQ AIMT) opened at 16.47 on Friday. The company’s market capitalization is $829.13 million. Aimmune Therapeutics has a 52 week low of $9.77 and a 52 week high of $27.31. The company has a 50-day moving average of $18.41 and a 200-day moving average of $20.14.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.05. On average, equities research analysts anticipate that Aimmune Therapeutics will post ($2.66) EPS for the current year.
Several brokerages have recently weighed in on AIMT. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, June 9th. ValuEngine upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Companies restated an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a report on Wednesday, March 22nd. Finally, Wedbush reiterated an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a research note on Friday, February 17th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $33.00.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Financial Market News and is the property of of Financial Market News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.financial-market-news.com/2017/06/17/aimmune-therapeutics-aimt-receiving-favorable-press-coverage-alphaone-reports.html.
In other news, CFO Warren L. Desouza sold 10,000 shares of the stock in a transaction on Tuesday, March 21st. The shares were sold at an average price of $22.95, for a total value of $229,500.00. Following the transaction, the chief financial officer now owns 30,681 shares of the company’s stock, valued at approximately $704,128.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Eric Bjerkholt purchased 5,000 shares of the firm’s stock in a transaction dated Friday, May 12th. The stock was bought at an average cost of $19.84 per share, for a total transaction of $99,200.00. Following the acquisition, the chief financial officer now directly owns 5,000 shares in the company, valued at $99,200. The disclosure for this purchase can be found here. Insiders sold a total of 25,600 shares of company stock worth $565,290 in the last three months. Insiders own 24.56% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.